Juul Wins UK Court Injunction, Ending Five-Year Legal Battle Against Chinese Vape Infringers

Oct.30
Juul Wins UK Court Injunction, Ending Five-Year Legal Battle Against Chinese Vape Infringers
The UK High Court has granted U.S. e-cigarette manufacturer Juul Labs a permanent injunction against four Chinese companies, bringing an end to a five-year patent and trademark infringement case. The defendants — Greensun Technology, Ouch, Gaish, and Airsmo Tech — failed to respond to any court communications or legal filings.

Key points

 

  • The UK High Court has granted U.S. vape maker Juul Labs a permanent injunction against four Chinese companies accused of patent and trademark infringement.

 

  • The defendants — Greensun Technology, Ouch, Gaish, and Airsmo Tech — failed to respond to any court communications or orders since 2019.

 

  • The injunction orders the destruction of all infringing products and requires the companies to publish the case outcome on their websites.

 

  • Juul’s case was delayed for years due to lack of cooperation and procedural stays, but the court ultimately ruled in its favor.

 

  • The ruling marks a major victory for Juul in its global intellectual property enforcement efforts.

 

According to a ruling by the UK High Court on October 29, vape manufacturer Juul Labs has won a long-running intellectual property dispute, with the court converting temporary injunctions issued in December 2019 into permanent ones. The ruling prohibits four Chinese companies from infringing on Juul’s trademarks, product designs, and patents.

 

The companies involved — Greensun Technology, Ouch, Gaish, and Airsmo Tech — are registered in mainland China and Hong Kong. Juul first discovered the infringing products at a UK trade show in 2019 and promptly sought interim injunctions. Over the following years, none of the four defendants responded to Juul’s communications, court orders, or any related legal documents.

 

Presiding Judge Timothy Fancourt stated that the defendants had “completely ignored the proceedings” and violated earlier court orders requiring them to submit witness statements detailing their infringing activities in the UK. Juul said that although the companies failed to engage, their infringing products were withdrawn from the UK market following the temporary injunction — indicating that the orders were effective.

 

Juul’s legal team noted that the lack of cooperation from the defendants led to delays in the case. Under UK civil procedure rules, a claim is automatically stayed if neither party takes action within six months. In addition, Juul had planned to consolidate the four cases, but its claim against Greensun was delayed for nearly four years due to administrative issues with Chinese authorities, further slowing the process.

 

The court’s latest decision not only prohibits the companies from supplying infringing products to the UK market in the future but also orders the destruction of existing infringing goods and requires the defendants to publish a notice of the ruling on their websites.

 

This case marks another significant step in Juul’s global intellectual property enforcement campaign. Although the defendants did not take part in the proceedings, the court upheld Juul’s claims of infringement, reaffirming the company’s trademark and patent protections in the UK market.

 

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Sweden on Track to Become Europe’s First Smoke-Free Nation as Snus and Nicotine Pouches Support Declining Smoking Rates
Sweden on Track to Become Europe’s First Smoke-Free Nation as Snus and Nicotine Pouches Support Declining Smoking Rates
According to Gulf News, Sweden is nearing the World Health Organization’s smoke-free threshold, with daily smoking falling below 5%. Two decades of public health efforts and the growing use of lower-risk alternatives such as Snus and tobacco-free nicotine pouches have contributed to this shift, alongside declines in tobacco-related deaths and lung cancer cases.
Dec.04 by 2FIRSTS.ai
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.
Dec.02 by 2FIRSTS.ai
2025 China Shenzhen Top 500 Enterprises List: 13 E-cigarette Companies Include
2025 China Shenzhen Top 500 Enterprises List: 13 E-cigarette Companies Include
Shenzhen e-commerce companies dominate 2025 Top 500 list, including 13 e-cigarette businesses. Shenzhen FirstUnion Tech climbs 57 spots.
Oct.30 by 2FIRSTS.ai
PMI’s Smoke-Free Playbook: What Jacek Olczak Really Told Wall Street
PMI’s Smoke-Free Playbook: What Jacek Olczak Really Told Wall Street
At the Morgan Stanley Global Consumer & Retail Conference on December 2, 2025, PMI CEO Jacek Olczak delivered a clear message: the company’s smoke-free shift is now its central strategy. From ZYN’s surge in the U.S. to IQOS’s global momentum and a changing regulatory tone, his remarks sounded less like an earnings update and more like a declaration of PMI’s smoke-free future.
PMI
Dec.03
France plans to impose new taxes on e-liquids, with the vape industry association warning of unemployment risk
France plans to impose new taxes on e-liquids, with the vape industry association warning of unemployment risk
French government proposes tax on e-liquid, sparking concerns over job losses and increased smuggling and underage sales risks.
Oct.16 by 2FIRSTS.ai
ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most
ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most
In a contribution to 2Firsts, U.S. regulatory consultancy ARAC analyzes the FDA’s nicotine pouch PMTA pilot, cautioning that core evidentiary standards remain unchanged. The firm warns against overinterpreting the pilot and urges companies to act now rather than wait for uncertain regulatory shifts.
Oct.21